Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
NCR Corporation (NCR - Analyst Report) recently announced a technical collaboration with SoloHealth, wherein NCR will install upgraded self-service healthcare kiosks across the U.S. These kiosks offer shoppers across the country easy access to health assessment procedures. NCR will also provide technical assistance to all the installed kiosks according to the terms of the agreement.
NCR has been consistently increasing its national footprint and enhancing its service quality. Through this collaboration, NCR technology will reach 2,500 retail locations, to which it is expected to help drive traffic.
The demand for self-service kiosks has increased considerably, as evident from the company’s recorded consumer interaction of above 3.2 million at the existing kiosks as of mid-October. Quality time has been spent by users in these kiosks and it has been seen that around 33% of users take more tests in these kiosks.
Healthcare is a comparatively new area of activity for NCR, as the company will be providing a cloud-based healthcare consumer platform, which is a new area of activity for NCR.
We remain highly positive about NCR’s position in the ATM and Point-of-Sale solutions (POS) segments. Moreover, as per the data collected by RBR from different banks and other deployers, the firm has made a "Global ATM Market and Forecast to 2013," which confirms NCR as the largest ATM manufacturer in the world with an installed base market share of 30.1%. RBR is also of the opinion that NCR holds a leadership position in China and North America, with an installed base market share of 32.0% and 26.4%, respectively.
We remain highly positive about NCR’s broad exposure in the ATM space. However, the market is not without competition, which comes in the form Diebold Inc. (DBD - Snapshot Report) and Wincor Nixdorf to name a few.
Currently, NCR has a Zacks #3 Rank (short-term Hold rating).
Get the full Analyst Report on NCR - FREE
Get the full Snapshot Report on DBD - FREE